Target family: Prostanoid receptors (type: gpcr)
Target: DP<sub>1</sub> receptor

Ligand: 15-deoxy-Δ12,14-PGJ2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: AH6809 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.8 pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: asapiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pKi
Reference (Patent): Sulfonamide derivative having PGD2 receptor antagonistic activity

Ligand: butaprost (free acid form) (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.9 pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: BW 245C (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
Published in: Br J Pharmacol

Ligand: BW 245C (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of the human prostanoid DP receptor.
Published in: J Biol Chem

Ligand: BW 245C (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: BW 245C (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.8 pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: BW 245C (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: BWA868C (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: BWA868C (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.7 pKi
Reference (Journal): Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
Published in: Br J Pharmacol

Ligand: BWA868C (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of the human prostanoid DP receptor.
Published in: J Biol Chem

Ligand: BWA868C (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective, and potent competitive antagonist.
Published in: Br J Pharmacol

Ligand: carbacyclin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: cloprostenol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.8 pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: Δ12-PGJ2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pKd
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: iloprost (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: EMA (2003), FDA (2004)
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: iloprost (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: EMA (2003), FDA (2004)
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
Published in: Biochem Pharmacol

Ligand: iloprost (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: EMA (2003), FDA (2004)
Primary target: no
Median affinity:  pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: L-644,698 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.8 pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: L-644,698 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: L-644,698 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: L-888,291 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.4 pKi
Reference (Journal): Identification of a potent and selective synthetic agonist at the CRTH2 receptor.
Published in: Mol Pharmacol

Ligand: laropiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.100000381469727 pKi
Reference (Journal): Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Published in: Clin Pharmacol Ther

Ligand: laropiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.100000381469727 pKi
Reference (Journal): Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
Published in: J Med Chem

Ligand: ONO-AE3-237 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKi
Reference (Journal): Prostanoid receptors.
Published in: Chem Rev

Ligand: ONO-AE3-237 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKi
Reference (Journal): Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists.
Published in: Bioorg Med Chem

Ligand: ONO-AE3-237 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKi
Reference (Journal): Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma.
Published in: J Immunol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
Published in: Br J Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pKi
Reference (Journal): Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
Published in: Br J Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of the human prostanoid DP receptor.
Published in: J Biol Chem

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Published in: Eur J Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: PGE1 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1981)
Median affinity: 7.3 pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: PGE2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1977)
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: PGE2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1977)
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of the human prostanoid DP receptor.
Published in: J Biol Chem

Ligand: PGE2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1977)
Median affinity:  pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: PGF2α (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: PGF2α (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: PGJ2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: RS 93520 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pKi
Reference (Journal): Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Published in: J Pharmacol Exp Ther

Ligand: S-5751 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751.
Published in: J Pharmacol Exp Ther

Ligand: SQ-27986 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Published in: J Pharmacol Exp Ther

Ligand: [3H]BWA868C (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.8 pKd
Reference (Journal): Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.
Published in: Br J Pharmacol

Ligand: [3H]PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: [3H]PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
Published in: Br J Pharmacol

Ligand: [3H]PGE2 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pKd

Ligand: TG11-77 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.139999866485596 pKB
Reference (Journal): Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models.
Published in: J Med Chem

Ligand: TG6-129 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.840000152587891 pKB
Reference (Journal): Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.
Published in: ACS Med Chem Lett

Ligand: treprostinil (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (2002), EMA (2020)
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity.
Published in: Prostaglandins Leukot Essent Fatty Acids

Ligand: treprostinil (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (2002), EMA (2020)
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
Published in: Biochem Pharmacol

Ligand: U46619 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Published in: Biochim Biophys Acta

Ligand: U46619 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: vidupiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.
Published in: ACS Med Chem Lett

Ligand: ZK110841 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.5 pKi
Reference (Journal): Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
Published in: Br J Pharmacol

Ligand: ZK118182 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKi
Reference (Journal): Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Published in: J Pharmacol Exp Ther